Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer

Hepatobiliary and Pancreatic Diseases International - Tập 18 - Trang 373-378 - 2019
June S Peng1, Jane Wey1, Sricharan Chalikonda1, Daniela S Allende2, R Matthew Walsh1, Gareth Morris-Stiff1
1Department of General Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA
2Department of Pathology, Pathology and Laboratory Medicine Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA

Tài liệu tham khảo

Cameron, 2015, Two thousand consecutive pancreaticoduodenectomies, J Am Coll Surg, 220, 530, 10.1016/j.jamcollsurg.2014.12.031

Katz, 2009, Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma, Ann Surg Oncol, 16, 836, 10.1245/s10434-008-0295-2

Zerón, 2009, Limitations in improving detection of pancreatic adenocarcinoma, Future Oncol, 5, 657, 10.2217/fon.09.32

Allen, 2016, Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer, Cochrane Database Syst Rev, 7

NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma, Version 2. 2018. Available athttps://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed 3 September 2018.

Katz, 2008, Borderline resectable pancreatic cancer: the importance of this emerging stage of disease, J Am Coll Surg, 206, 833, 10.1016/j.jamcollsurg.2007.12.020

He, 2014, Management of borderline and locally advanced pancreatic cancer: where do we stand?, World J Gastroenterol, 20, 2255, 10.3748/wjg.v20.i9.2255

Katz, 2012, Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators, Cancer, 118, 5749, 10.1002/cncr.27636

Cloyd, 2017, Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma, JAMA Surg, 152, 1048, 10.1001/jamasurg.2017.2227

Adsay, 2014, Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors, Am J Surg Pathol, 38, 480, 10.1097/PAS.0000000000000165

Kakar S, Shi C, Adsay NV, Fitzgibbons P, Frankel WL, Klimstra DS, et al. Protocol for the examination of specimens from patients with carcinoma of the pancreas. Version 4.0.0.1 (2017). Available athttp://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-pancreas-exocrine-17protocol-4001.pdf. Accessed 16 February 2018.

Chirieac, 2005, Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation, Cancer, 103, 1347, 10.1002/cncr.20916

Donahue, 2009, Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival, Ann Thorac Surg, 87, 392, 10.1016/j.athoracsur.2008.11.001

Maas, 2010, Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data, Lancet Oncol, 11, 835, 10.1016/S1470-2045(10)70172-8

Habr-Gama, 2013, Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?, Dis Colon Rectum, 56, 1109, 10.1097/DCR.0b013e3182a25c4e

Yang, 2015, Predicting complete response: is there a role for non-operative management of rectal cancer?, J Gastrointest Oncol, 6, 241

Peng, 2017, Diagnostic laparoscopy prior to neoadjuvant therapy in pancreatic cancer is high yield: an analysis of outcomes and costs, J Gastrointest Surg, 21, 1420, 10.1007/s11605-017-3470-6

Katz, 2016, Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101, JAMA Surg, 151, 10.1001/jamasurg.2016.1137

Patel, 2011, Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer, J Surg Oncol, 104, 155, 10.1002/jso.21954

Addeo, 2015, Resection of borderline resectable and locally advanced pancreatic adenocarcinomas after neoadjuvant chemotherapy, Oncology, 89, 37, 10.1159/000371745

Nanda, 2015, Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability, J Surg Oncol, 111, 1028, 10.1002/jso.23921

Sherman, 2015, Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma, Cancer, 121, 673, 10.1002/cncr.29112

Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923

Conroy, 2018, Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas, J Clin Oncol, 379, 2395

Rombouts, 2016, Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer, Ann Surg Oncol, 23, 4352, 10.1245/s10434-016-5373-2

Thông tin
Thông tin xuất bản

Hepatobiliary and Pancreatic Diseases International

Tập 18

373-378

Thông tin tác giả